BioNTech SE Files Form 6-K with SEC
Ticker: BNTX · Form: 6-K · Filed: Apr 2, 2025 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Apr 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, disclosure
TL;DR
BioNTech filed a 6-K on April 2, 2025, confirming a December 23, 2024 term sheet.
AI Summary
BioNTech SE announced on April 2, 2025, that it entered into a binding term sheet on December 23, 2024. The filing is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC.
Why It Matters
This filing indicates ongoing corporate activities and disclosures by BioNTech SE to the U.S. Securities and Exchange Commission, providing transparency to investors.
Risk Assessment
Risk Level: low — The filing is a routine SEC disclosure for a foreign private issuer and does not contain new material financial or operational information.
Key Players & Entities
- BioNTech SE (company) — Registrant
- December 23, 2024 (date) — Date of Term Sheet
- April 2, 2025 (date) — Filing Date
FAQ
What type of SEC filing is this?
This is a Form 6-K, a report of a foreign private issuer.
When did BioNTech SE enter into the binding term sheet?
BioNTech SE entered into the binding term sheet on December 23, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at An der Goldgrube 12, D-55131 Mainz, Germany.
Does BioNTech SE file annual reports under Form 20-F?
Yes, BioNTech SE indicates it files annual reports under Form 20-F.
What is the SEC file number for BioNTech SE?
The SEC file number for BioNTech SE is 001-39081.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 2, 2025 regarding BioNTech SE (BNTX).